Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Profarma Distribuidora De Produtos Farmaceuticos Debt-to-EBITDA Related Terms
Profarma Distribuidora De Produtos Farmaceuticos Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profarma Distribuidora De Produtos Farmaceuticos Debt-to-EBITDA Chart
Profarma Distribuidora De Produtos Farmaceuticos Annual Data
BSP:PFRM3 vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Profarma Distribuidora De Produtos Farmaceuticos's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profarma Distribuidora De Produtos Farmaceuticos Debt-to-EBITDA vs Medical Distribution Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) has a Debt-to-EBITDA of 1.99 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Profarma Distribuidora De Produtos Farmaceuticos. This is 50% below median its historical median of 4.02. Over the past decade, Profarma Distribuidora De Produtos Farmaceuticos' Debt-to-EBITDA has ranged from 2.70 to 18.39. According to the industry distribution chart, Profarma Distribuidora De Produtos Farmaceuticos ranks #53 out of 91 companies in the Medical Distribution industry, placing it in the top 58.2%.
Is Profarma Distribuidora De Produtos Farmaceuticos' Debt-to-EBITDA too high?
Profarma Distribuidora De Produtos Farmaceuticos' current Debt-to-EBITDA of 1.99 is 50% below median its 10-year median of 4.02. Over the past 10 years, this metric has ranged from a low of 2.70 to a high of 18.39. The Medical Distribution industry median Debt-to-EBITDA is 2.29. Profarma Distribuidora De Produtos Farmaceuticos' value of 1.99 is 13.1% below this industry median. Based on the distribution chart, Profarma Distribuidora De Produtos Farmaceuticos ranks #53 out of 91 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Profarma Distribuidora De Produtos Farmaceuticos has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Profarma Distribuidora De Produtos Farmaceuticos' Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Profarma Distribuidora De Produtos Farmaceuticos ranks #53 out of 91 companies for Debt-to-EBITDA. This places Profarma Distribuidora De Produtos Farmaceuticos in the lower half of its industry. The industry median Debt-to-EBITDA is 2.29. Profarma Distribuidora De Produtos Farmaceuticos' value of 1.99 is 13.1% below this benchmark. Historically, Profarma Distribuidora De Produtos Farmaceuticos' own Debt-to-EBITDA has ranged from 2.70 to 18.39 over the past decade. While the company's 10-year median is 4.02 vs. the industry median of 2.29, Profarma Distribuidora De Produtos Farmaceuticos has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.29, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profarma Distribuidora De Produtos Farmaceuticos's current Debt-to-EBITDA of 1.99 is 13.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Profarma Distribuidora De Produtos Farmaceuticos. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profarma Distribuidora De Produtos Farmaceuticos's current Debt-to-EBITDA is 1.99, which is 50% below median its own 10-year median of 4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profarma Distribuidora De Produtos Farmaceuticos stock overvalued right now?
Based on GuruFocus' analysis, Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.46, compared to a current price of R$7.05 — trading 16.7% below its estimated fair value. The current Debt-to-EBITDA is 1.99, which is 50% below median its 10-year median of 4.02 and 13.1% below the Medical Distribution industry median of 2.29. Profarma Distribuidora De Produtos Farmaceuticos' overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3), the current Debt-to-EBITDA is 1.99 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) Overvalued in 2026?
Based on GuruFocus' analysis, Profarma Distribuidora De Produtos Farmaceuticos stock appears to be undervalued.
The current stock price of R$7.05 is trading 16.7% below its estimated GF Value™ of R$8.46.
GuruFocus considers Profarma Distribuidora De Produtos Farmaceuticos to be Modestly Undervalued.
Key valuation signals for BSP:PFRM3:
Debt-to-EBITDA: 1.99 (50% below median its 10-year median of 4.02)
GF Value™: R$8.46 vs. price of R$7.05 (16.7% below fair value)
Industry Position: 13.1% below the Medical Distribution median (#53 of 91)
No single metric tells the full story. See the BSP:PFRM3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profarma Distribuidora De Produtos Farmaceuticos SA is a Brazil-based company. It is engaged in wholesale and distribution of pharmaceuticals, cosmetics and similar products, and toiletries. Profarma also holds interests in other companies, regardless of their business sector. The company through its logistics department distributes products in the South, Southeast, Northeast and Center-West regions of Brazil. The firm operates in the pharmaceutical distribution, hospital and specialty, retail segments.
78GF Score
Get the complete analysis for BSP:PFRM3
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:PFRM3 has been successfully added to your 
